This test provides adalimumab drug concentration levels as well as the level of antiadalimumab antibodies
Monitor antiadalimumab therapy for individuals with Crohn's disease, inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, or other autoimmune conditions
Immediatley following collection, mix sample by gently inverting 5 times
Gold serum separator (SST) tube
Refrigerated (preferred) - 7 days
Ambient - 7 days
Frozen - 308 days
Electrochemiluminescence Immunoassay (ECLIA)
Adalimumab drug level:
Quantitation limit: <0.6 μg/mL
Results ≥0.6 μg/mL indicate detection of adalimumab.
In the presence of antiadalimumab antibody, the adalimumab drug level reflects the antibody-unbound fraction of adalimumab concentration in serum.
Quantitation limit: <25 ng/mL
Results ≥25 ng/mL indicate detection of adalimumab antibody